<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239901</url>
  </required_header>
  <id_info>
    <org_study_id>1RC1HL099412-01</org_study_id>
    <nct_id>NCT01239901</nct_id>
  </id_info>
  <brief_title>Iron Mediated Vascular Disease in Sickle Cell Anemia Patients</brief_title>
  <official_title>Iron-mediated Vascular Disease in Sickle Cell Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine the frequency and severity of iron
      overload in patients with Sickle Cell Anemia and its relationship to blood vessel function.
      The investigators hypothesize that intermittent transfusions that these patients receive
      during hospitalizations produces significant iron overload and impairs blood vessel
      relaxation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with sickle cell anemia often require blood transfusion as part of the treatment for
      their disease. Each teaspoon of transfused blood contains about 5 mg of iron and the levels
      of iron in sickle cell patients increase rapidly with each transfusion. While iron is
      necessary for many bodily functions, too much iron damages blood vessels, liver, hormone
      producing glands (pancreas, pituitary and thyroid) and the heart. It is important to know how
      iron damages blood vessels because most of the problems experienced by sickle cell anemia
      patients (stroke, kidney failure, pulmonary hypertension, heart disease) result from blood
      vessel damage. In this trial, iron in the liver, pancreas, and kidney will be measured
      noninvasively by MRI while vascular function will be measured by ultrasound and tissue
      Doppler. Patients will be recruited primarily from the greater Los Angeles area, although
      patients from greater distances will be allowed to participate.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Liver iron concentration (LIC), pancreas R2*, and kidney R2*, measured by MRI</measure>
    <time_frame>15 min MRI done completed during one time study visit</time_frame>
    <description>Liver iron concentration (LIC) will be used as a surrogate for total body iron, pancreatic iron represents a surrogate for extravascular iron deposition, and renal iron as a surrogate for chronic intravascular hemolysis. In addition, labile plasma iron will be measured in blood plasma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vascular function.</measure>
    <time_frame>Scheduled during one time study visit</time_frame>
    <description>Measurements will be done through several procedures: Ultrasound of artery in upper arm, Ultrasound of artery in neck, and blood tests of ascorbate and hydrobiopterins.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Sickle Cell Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Red Blood Cells (RBCs), Peripheral Blood Mononuclear Cells (PBMCs), Plasma, Serum, and Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Our large and well-established sickle cell Center has strong ties to the SCD community in a
        large metropolitan area (Los Angeles), placing us in an ideal position to rapidly accrue
        sufficient subjects to study the prevalence of iron overload and determine the relation
        between directly measured iron loading, vascular responsiveness and clinically relevant
        biomarkers of vascular function.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 13 years

          -  Documented diagnosis of sickle cell anemia (SS, SC, Sß0, Sß+)

          -  Transfused no more than 8 times in a year.

        Exclusion Criteria:

          -  Cardiac pacemaker, implantable neurostimulator or other MRI incompatible device.

          -  History of extreme claustrophobia in MRI machine or other reason for inability to do
             MRI without sedation.

          -  Inability to be positioned on the MRI table for sufficient time to complete the MRI
             exams.

          -  Any medical or psychological condition that, in the opinion of the local investigator,
             would make it unsafe or ill-advised for the subject to participate.

          -  Currently not receiving chronic transfusion therapy, defined as greater than 8
             transfusions per year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C Wood, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol. 2001 Jan;38(1 Suppl 1):30-6.</citation>
    <PMID>11206959</PMID>
  </reference>
  <reference>
    <citation>Cheung YF, Chan GC, Ha SY. Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major. Br J Haematol. 2008 May;141(5):728-33. doi: 10.1111/j.1365-2141.2008.07092.x. Epub 2008 Mar 3.</citation>
    <PMID>18318756</PMID>
  </reference>
  <reference>
    <citation>Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004 Oct;89(10):1187-93.</citation>
    <PMID>15477202</PMID>
  </reference>
  <reference>
    <citation>Pakbaz Z, Fischer R, Fung E, Nielsen P, Harmatz P, Vichinsky E. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer. 2007 Sep;49(3):329-32.</citation>
    <PMID>17554789</PMID>
  </reference>
  <reference>
    <citation>Schein A, Enriquez C, Coates TD, Wood JC. Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis. J Magn Reson Imaging. 2008 Sep;28(3):698-704. doi: 10.1002/jmri.21490.</citation>
    <PMID>18777554</PMID>
  </reference>
  <reference>
    <citation>Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, Coates TD. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005 Aug 15;106(4):1460-5. Epub 2005 Apr 28.</citation>
    <PMID>15860670</PMID>
  </reference>
  <reference>
    <citation>Wood JC, Enriquez C, Ghugre N, Otto-Duessel M, Aguilar M, Nelson MD, Moats R, Coates TD. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci. 2005;1054:386-95. Review.</citation>
    <PMID>16339687</PMID>
  </reference>
  <reference>
    <citation>Ganz T. Molecular control of iron transport. J Am Soc Nephrol. 2007 Feb;18(2):394-400. Epub 2007 Jan 17. Review.</citation>
    <PMID>17229910</PMID>
  </reference>
  <reference>
    <citation>Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med (Berl). 2006 May;84(5):349-64. Epub 2006 Apr 8. Review.</citation>
    <PMID>16604332</PMID>
  </reference>
  <reference>
    <citation>Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, Porter J, Evans P, Vichinsky E, Harmatz P. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006 Oct;135(2):254-63.</citation>
    <PMID>17010049</PMID>
  </reference>
  <reference>
    <citation>Kato GJ, Gladwin MT. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA. 2008 Dec 10;300(22):2638-46. doi: 10.1001/jama.2008.598. Review.</citation>
    <PMID>19066384</PMID>
  </reference>
  <reference>
    <citation>Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf). 2009 Jun;196(2):193-222. doi: 10.1111/j.1748-1716.2009.01964.x. Epub 2009 Feb 10. Review.</citation>
    <PMID>19220204</PMID>
  </reference>
  <reference>
    <citation>Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM Jr, Gladwin MT. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005 Jul 6;294(1):81-90.</citation>
    <PMID>15998894</PMID>
  </reference>
  <reference>
    <citation>Werner ER, Gorren AC, Heller R, Werner-Felmayer G, Mayer B. Tetrahydrobiopterin and nitric oxide: mechanistic and pharmacological aspects. Exp Biol Med (Maywood). 2003 Dec;228(11):1291-302. Review.</citation>
    <PMID>14681545</PMID>
  </reference>
  <reference>
    <citation>Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, Fargion S. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol. 2007 Jun;102(6):1251-8. Epub 2007 Mar 27.</citation>
    <PMID>17391316</PMID>
  </reference>
  <reference>
    <citation>Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007 Apr 10;115(14):1876-84. Epub 2007 Mar 19.</citation>
    <PMID>17372174</PMID>
  </reference>
  <reference>
    <citation>Castro O, Haddy TB. Improved survival of iron-deficient patients with sickle erythrocytes. N Engl J Med. 1983 Mar 3;308(9):527.</citation>
    <PMID>6823275</PMID>
  </reference>
  <reference>
    <citation>Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004 Feb 26;350(9):886-95.</citation>
    <PMID>14985486</PMID>
  </reference>
  <reference>
    <citation>de Montalembert M, Aggoun Y, Niakate A, Szezepanski I, Bonnet D. Endothelial-dependent vasodilation is impaired in children with sickle cell disease. Haematologica. 2007 Dec;92(12):1709-10.</citation>
    <PMID>18055999</PMID>
  </reference>
  <reference>
    <citation>Belhassen L, Pelle G, Sediame S, Bachir D, Carville C, Bucherer C, Lacombe C, Galacteros F, Adnot S. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood. 2001 Mar 15;97(6):1584-9.</citation>
    <PMID>11238095</PMID>
  </reference>
  <reference>
    <citation>Takeda M, Yamashita T, Shinohara M, Sasaki N, Takaya T, Nakajima K, Inoue N, Masano T, Tawa H, Satomi-Kobayashi S, Toh R, Sugiyama D, Nishimura K, Yokoyama M, Hirata K, Kawashima S. Plasma tetrahydrobiopterin/dihydrobiopterin ratio: a possible marker of endothelial dysfunction. Circ J. 2009 May;73(5):955-62. Epub 2009 Mar 18.</citation>
    <PMID>19293532</PMID>
  </reference>
  <reference>
    <citation>Gonzalez J, Wood JC, Dorey FJ, Wren TA, Gilsanz V. Reproducibility of carotid intima-media thickness measurements in young adults. Radiology. 2008 May;247(2):465-71. doi: 10.1148/radiol.2472070691. Epub 2008 Mar 18.</citation>
    <PMID>18349312</PMID>
  </reference>
  <reference>
    <citation>Cheung YF, Chow PC, Chan GC, Ha SY. Carotid intima-media thickness is increased and related to arterial stiffening in patients with beta-thalassaemia major. Br J Haematol. 2006 Dec;135(5):732-4.</citation>
    <PMID>17107355</PMID>
  </reference>
  <reference>
    <citation>Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006 Mar 15;107(6):2279-85. Epub 2005 Nov 15.</citation>
    <PMID>16291595</PMID>
  </reference>
  <reference>
    <citation>Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, Steinberg MH, Vichinsky EP, Shigenaga M, Ames B, Kuypers FA, Klings ES. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood. 2008 Jan 1;111(1):402-10. Epub 2007 Sep 11.</citation>
    <PMID>17848621</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>John C. Wood</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics - Division of Cardiology</investigator_title>
  </responsible_party>
  <keyword>sickle cell disease</keyword>
  <keyword>sickle cell anemia</keyword>
  <keyword>sickled cells</keyword>
  <keyword>blood vessel</keyword>
  <keyword>iron overload</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

